ANL 32.50 Decreased By ▼ -0.30 (-0.91%)
ASC 14.38 Decreased By ▼ -0.22 (-1.51%)
ASL 22.65 Decreased By ▼ -0.24 (-1.05%)
AVN 86.95 Decreased By ▼ -0.93 (-1.06%)
BOP 7.92 Decreased By ▼ -0.05 (-0.63%)
BYCO 9.94 Decreased By ▼ -0.02 (-0.2%)
DGKC 116.00 Decreased By ▼ -0.20 (-0.17%)
EPCL 52.50 Decreased By ▼ -1.00 (-1.87%)
FCCL 23.25 Decreased By ▼ -0.43 (-1.82%)
FFBL 26.65 Decreased By ▼ -0.90 (-3.27%)
FFL 15.20 Decreased By ▼ -0.10 (-0.65%)
HASCOL 9.15 Decreased By ▼ -0.10 (-1.08%)
HUBC 75.50 Decreased By ▼ -1.00 (-1.31%)
HUMNL 6.15 Decreased By ▼ -0.04 (-0.65%)
JSCL 20.15 Decreased By ▼ -0.36 (-1.76%)
KAPCO 38.10 Decreased By ▼ -0.60 (-1.55%)
KEL 3.70 Decreased By ▼ -0.06 (-1.6%)
LOTCHEM 15.00 Decreased By ▼ -0.50 (-3.23%)
MLCF 42.99 Decreased By ▼ -0.76 (-1.74%)
PAEL 32.57 Decreased By ▼ -0.13 (-0.4%)
PIBTL 10.00 Increased By ▲ 0.05 (0.5%)
POWER 8.79 Increased By ▲ 0.14 (1.62%)
PPL 82.30 Decreased By ▼ -1.00 (-1.2%)
PRL 24.10 Increased By ▲ 0.05 (0.21%)
PTC 9.11 Decreased By ▼ -0.04 (-0.44%)
SILK 1.33 Decreased By ▼ -0.03 (-2.21%)
SNGP 39.10 Decreased By ▼ -0.25 (-0.64%)
TRG 176.00 Increased By ▲ 5.00 (2.92%)
UNITY 30.75 Decreased By ▼ -0.50 (-1.6%)
WTL 1.55 Increased By ▲ 0.03 (1.97%)
BR100 4,795 Decreased By ▼ -29.74 (-0.62%)
BR30 24,960 Decreased By ▼ -99.54 (-0.4%)
KSE100 44,707 Decreased By ▼ -222.85 (-0.5%)
KSE30 18,276 Decreased By ▼ -98.7 (-0.54%)

Coronavirus
VERY HIGH
Pakistan Deaths
16,842
14424hr
Pakistan Cases
784,108
587024hr
Sindh
275,815
Punjab
282,469
Balochistan
21,365
Islamabad
72,150
KPK
110,875
Business & Finance

Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient in US

  • The price for US private insurance companies will be $520 per vial, the drugmaker said, which equates to a total of $3,120 per patient.
  • After this period, once supplies are less constrained, HHS will stop managing the allocation, the company said.
29 Jun 2020

Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $390 per vial for the United States and governments of other developed countries, it said on Monday, setting the price of a five-day course at $2,340 per patient.

The price for US private insurance companies will be $520 per vial, the drugmaker said, which equates to a total of $3,120 per patient.

Gilead has entered into an agreement with the US Department of Health and Human Services (HHS) whereby the department and states will manage allocation to hospitals until September end.

After this period, once supplies are less constrained, HHS will stop managing the allocation, the company said.

Remdesivir's price has been a topic of intense debate since the US Food and Drug Administration approved its emergency use COVID-19 patients in May.

Experts have suggested that Gilead would need to avoid the appearance of taking advantage of a health crisis for profits.

Wall Street analysts have said the antiviral drug could generate billions of dollars in revenue over the next couple of years if the pandemic continues.